What is Competitive Landscape of Elekta Company?

How is Elekta navigating today’s radiation oncology market?

The 2025 commercial launch of the Elekta Evo CT-Linac signals a push to regain market momentum with high-definition imaging and faster treatments. Founded in 1972 in Stockholm to commercialize the Gamma Knife, Elekta evolved from niche innovator to global cancer-care systems provider.

Elekta competes against large medtech conglomerates and focused radiotherapy firms across hardware, software and services; key strengths include installed base of over 7,000 systems and global reach in >120 countries. See Elekta Porter's Five Forces Analysis for framework-based insights.

Elekta delivers precision radiation oncology systems and software, combining advanced linear accelerators, MR-guided therapy and stereotactic radiosurgery with growing SaaS clinical platforms to improve patient outcomes and operational efficiency.

Market ranking

As of early 2026 Elekta holds an estimated 32%–34% share of the global external beam radiation therapy market, placing it firmly in second place behind Varian.

Revenue mix

For fiscal 2024/25 Elekta reported net sales above 18.8 billion SEK, with services now contributing nearly 45% of total revenue.

Product portfolio

Core segments are Oncology Treatment Solutions (Versa HD, Unity MR‑Linac) and Neuro Care (Leksell Gamma Knife), supporting both high-end and mid-tier clinical needs.

Geographic strength

Balanced footprint with strong installation growth in China and India, where mid-tier offerings drive market share gains versus larger rivals.

Elekta competes in a duopoly-like landscape against Siemens Healthineers/Varian, which controls roughly ~52% of the external beam market; Elekta’s North American share remains nearer 20%, prompting strategic initiatives to regain ground.

Strategic positioning and digital shift

Elekta has accelerated a digital transformation toward SaaS with MOSAIQ and Elekta ONE to stabilize margins and capture recurring revenue, targeting an EBIT margin of 14%–16% by end of 2025/26.

• Strength: Specialized oncology focus enables faster clinical feature delivery and clinician alignment
• Weakness: Smaller scale versus Siemens‑Varian limits pricing leverage in some regions
• Opportunity: Continued APAC expansion and mid-tier product demand can boost installations and service revenue
• Threat: Varian dominance in North America and consolidation among medical device competitors

For further reading on strategic moves and market positioning, see Growth Strategy of Elekta

Complete Elekta Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Elekta generates revenue from sales of linear accelerators, MR‑Linacs, brachytherapy systems, and services including maintenance, software subscriptions, and upgrades. In 2025 Elekta reported service and software contributing about 45% of recurring revenue, with hardware sales and disposables making up the remainder.

Monetization leverages capital equipment sales, long‑term service contracts, oncology informatics subscriptions, and customer financing. Cross‑selling imaging‑to‑therapy workflows and training increases lifetime customer value.

Varian (Siemens Healthineers)

After Siemens’ acquisition of Varian for 16.4 billion USD, Varian leverages Siemens’ imaging base to offer integrated diagnostic-to-treatment workflows like Ethos, pressuring Elekta in single‑vendor preference markets.

Accuray

Accuray holds roughly 5–7% global share with CyberKnife and Radixact; its motion‑synchronization precision challenges Elekta in stereotactic body radiotherapy segments.

United Imaging Healthcare

In China, United Imaging benefits from domestic procurement policies and R&D in high‑end imaging and radiotherapy, posing a strong regional threat to Elekta’s growth in emerging markets.

GE Healthcare & Philips

Major imaging firms compete indirectly via oncology informatics and MR partnerships; both firms can erode Elekta’s software and MR‑guided therapy positioning despite occasional collaborations.

ViewRay (market exit)

ViewRay exited in 2024, consolidating the MR‑Linac market around Elekta Unity as the primary high‑field option, though Varian’s lower‑field adaptive systems and Chinese entrants are emerging competitors.

Regional and Diversified Tech Firms

Smaller regional manufacturers and diversified tech firms develop niche or software‑first oncology solutions, challenging Elekta on pricing, localization, and hybrid service models.

The Elekta competitive analysis shows Varian/Siemens as the dominant direct rival, with Accuray, United Imaging, and major imaging firms shaping the radiation oncology market dynamics; see Target Market of Elekta for related context.

Competitive Implications

Key takeaways for Elekta market position and strategy:

• Single‑vendor imaging+therapy offerings give Varian a competitive edge in high‑income hospital systems.
• Service and software recurring revenues (~45%) are critical to defend margins and customer retention.
• Accuray’s SRS/SBRT precision targets high‑margin therapy niches where Elekta must innovate.
• Domestic champions like United Imaging can capture emerging‑market share via localization and pricing.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Elekta’s MR-Linac leadership and Leksell Gamma Knife heritage anchor its market position; the company held a notable share of the high-precision radiotherapy segment by 2025. Strategic partnerships, including the 2024 expansion with GE Healthcare, and an open-ecosystem software stance underpin cost-efficient growth in emerging markets.

Key milestones include commercialization of the 1.5T Elekta Unity MR-Linac, expansion of MOSAIQ interoperability, and maintaining a portfolio of over 2,500 patents that protect clinical innovation and market differentiation.

Technological Moat

Elekta Unity remains the only high-field 1.5 Tesla MR-Linac on the market as of 2025, enabling real-time, diagnostic-quality imaging during treatment and creating a durable competitive edge.

Brand Leadership

The Leksell Gamma Knife retains near-synonymous status with intracranial radiosurgery, driving clinician preference and deep customer loyalty among neurosurgeons and oncologists.

Open Ecosystem

MOSAIQ’s vendor-neutral architecture supports devices from Varian and Accuray, making Elekta attractive to multi-vendor clinics and large health systems seeking to avoid vendor lock-in.

Lean Partnerships

The 2024 deepening of the GE Healthcare partnership expanded imaging-to-treatment bundles without Elekta owning a diagnostic imaging division, improving capital efficiency.

These competitive advantages translate into commercial outcomes: by 2025 Elekta reported strong order intake for high-value systems, sustained recurring software and service revenues, and growing share in several emerging markets where precision radiotherapy adoption increased year-over-year.

Strategic Implications

Elekta’s positioning emphasizes precision, interoperability, and partnership-led scale, affecting its competitive dynamics across the radiation oncology market.

• Proprietary advantage: over 2,500 patents protect MR-guided therapy and Gamma Knife technologies
• Market trust: Leksell Gamma Knife holds leadership in intracranial radiosurgery adoption
• Interoperability: MOSAIQ supports multi-vendor clinical environments, reducing vendor lock-in
• Partnership model: alliance with GE Healthcare broadens solutions without heavy capital investment

See further financial and business-model detail in Revenue Streams & Business Model of Elekta for context on how these advantages drive recurring revenue and margins in the Elekta competitive analysis and industry landscape.

Elekta Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Elekta occupies a leading position in the global radiation oncology market, driven by strengths in precision linear accelerators and software-driven adaptive therapies, but faces measurable risks from intensifying competition and geopolitical supply-chain pressures; the company’s future outlook depends on successful AI integration, regulatory compliance cost management, and expansion into theranostics and combo-immuno-radiotherapy workflows.

Key near-term risks include reimbursement shifts in the US toward value-based care, increased Medical Device Regulation compliance costs in Europe, and China market access volatility; opportunities center on hypofractionation adoption, workflow automation with generative AI, and partnerships that position Elekta systems as preferred delivery platforms for multimodal oncology treatments.

AI-driven treatment planning

Generative AI and machine learning are core to modern treatment planning, cutting dose-calculation time from hours to minutes and addressing workforce shortages of medical physicists and radiation therapists.

Hypofractionation adoption

Shift toward fewer, higher-dose fractions increases demand for sub-millimeter precision; vendors with proven adaptive radiotherapy and real-time imaging capabilities gain competitive advantage.

Regulatory and reimbursement pressure

Europe’s MDR raises compliance costs that favor established players, while US value-based reimbursement requires demonstrable outcome and efficiency gains from equipment investments.

Theranostics and multimodal therapy

Emerging theranostics and combinations of immunotherapy plus radiotherapy create demand for integrated delivery platforms and coordinated clinical workflows.

Market participants should note volume and share signals: as of 2025, Elekta reported annual revenue near SEK 16.3 billion (2025 FY reported), holding a top-three position globally alongside Varian (Siemens Healthineers/Varian combined market dynamics) and other key competitors; capital expenditures and R&D intensity remain critical to defend market position.

Competitive pressures and strategic levers

Elekta’s competitive analysis must factor technology leadership, installed base service economics, and market access risks while exploiting AI, hypofractionation, and theranostics partnerships.

• AI/automation: accelerates planning and throughput, addressing workforce shortages and lowering operational cost per treatment.
• Precision: hypofractionation increases value for high-precision systems; clinical evidence will drive procurement decisions.
• Regulation: MDR compliance elevates barriers to entry in Europe; incumbents with scale gain advantage.
• Geopolitics: supply-chain and China access risks require diversified sourcing and local partnerships to protect revenue.

For further context on strategic positioning and go-to-market approaches, see Marketing Strategy of Elekta

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE